patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline patients experiencing cerebral hemorrhage or cerebral infarction at baseline alt/ast > 5 times the upper limit of normal; child-pugh score 10 to 15 stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30) patients on mechanical ventilation or extracorporeal membrane oxygenation (ecmo) patients taking droxidopa pregnant and lactating women and those planning to get pregnant known or suspected allergy to the trial drug or the relevant drugs given in the trial presence of other disease that may interfere with testing procedures or in the judgement of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial know inability of patient to comply with the protocol for the duration of the study involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. participation in observational registry studies is permitted.

patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline patients experiencing cerebral hemorrhage or cerebral infarction at baseline alt/ast > 5 times the upper limit of normal; child-pugh score 10 to 15 stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30) patients on mechanical ventilation or extracorporeal membrane oxygenation (ecmo) patients taking droxidopa pregnant and lactating women and those planning to get pregnant known or suspected allergy to the trial drug or the relevant drugs given in the trial presence of other disease that may interfere with testing procedures or in the judgement of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial know inability of patient to comply with the protocol for the duration of the study involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. participation in observational registry studies is permitted.

1. patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline 2. patients experiencing cerebral hemorrhage or cerebral infarction at baseline 3. alt/ast > 5 times the upper limit of normal; child-pugh score 10 to 15 4. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30) 5. patients on mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 6. patients taking droxidopa 7. pregnant and lactating women and those planning to get pregnant 8. known or suspected allergy to the trial drug or the relevant drugs given in the trial 9. presence of other disease that may interfere with testing procedures or in the judgement of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial 10. know inability of patient to comply with the protocol for the duration of the study 11. involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. participation in observational registry studies is permitted.

1. patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline 2. patients experiencing cerebral hemorrhage or cerebral infarction at baseline 3. alt/ast > 5 times the upper limit of normal; child-pugh score 10 to 15 4. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30) 5. patients on mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 6. patients taking droxidopa 7. pregnant and lactating women and those planning to get pregnant 8. known or suspected allergy to the trial drug or the relevant drugs given in the trial 9. presence of other disease that may interfere with testing procedures or in the judgement of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial 10. know inability of patient to comply with the protocol for the duration of the study 11. involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. participation in observational registry studies is permitted.